Study | SUD assessment | Acute (after daily DTMS) assessment | Last follow-up assessmenta | Treatment strategyb | Study design | Study groups |
---|---|---|---|---|---|---|
Alcohol | ||||||
 Rapinesi et al., 2013 [17] | OCDS | Session 20 | 6 months | add-on | open-label (case study) | 1 group: DTMS |
 Rapinesi et al., 2014 [19] | OCDS | Session 20 | 12 months | add-on | open-label (case study) | 1 group: DTMS |
 Ceccanti et al., 2015 [20] | VAS, TLFB, blood prolactin | Session 10 | 2–3 months | monotherapy | RCT | 2 groups (both with cue conditionc): DTMS vs. sham |
 Girardi et al., 2015 [21] | OCDS | Session 20 | 6 months | add-on | open-label | 2 groups: DTMS vs. STD (no DTMS) |
 Rapinesi et al., 2015 [22] | OCDS | Session 20 | 6 months | add-on | open-label | 2 groups: DTMS (MDD + AUD) vs. DTMS (MDD) |
 Addolorato et al., 2017 [25] | OCDS, ADS, TLFB, SPECT | Session 12 | – | monotherapy | RCT | 3 groups: DTMS vs. sham vs. healthy (no DTMS) |
Nicotine | ||||||
 Dinur-Klein et al., 2014 [18] | FTND, sTCQ, urine analysis | Session 13 | 6 months | monotherapy | RCT | 6 groups (each with or without cue conditionc): DTMS (10 Hz) vs. DTMS (1 Hz) vs. sham |
Cocaine | ||||||
 Bolloni et al., 2016 [24] | Hair analysis | Session 12 | 6 months | monotherapy | RCT | 2 groups: DTMS vs. sham |
 Rapinesi et al., 2016 [23] | VAS | Session 12 | 2 months | add-on | open-label | 1 group: DTMS |